Scalper1 News
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck’s (MRK) earnings totaled 85 cents a share, up a penny from the year-earlier quarter and beating analysts’ consensus by 4 cents. Sales shrank 1% to $10.9 billion due to patent losses but still beat the Street’s expectations by about $300 Scalper1 News
Scalper1 News